While it may not receive as much attention as major exchanges, the OTC market offers an array of underappreciated stocks trading below 5 cents. Today, we'll explore four such stocks that have the potential to be breakout stocks. Despite flying under the radar, these stocks possess unique qualities and untapped potential that even experienced investors may find surprising. Join us as we dive into the depths of the OTC market for some hidden gems under 5 cents.
3DX Industries Inc. (OTC: DDDX)
Key Highlights:
Expanding global 3D printing market is projected to exceed USD 98.31 billion by 2032, growing at a CAGR of 18.92%.
Expertise in advanced manufacturing techniques utilizing state-of-the-art 3D Metal Printing Systems, Composite Printing equipment, and CNC Precision Machining Centers
Strategic positioning in growing sectors like aerospace, automotive, and healthcare.
Recent equipment upgrades to enhance production efficiencies.
Amidst the realm of undervalued OTC companies, 3DX Industries Inc. (OTC: DDDX) emerges as an intriguing candidate in the precision manufacturing sector. With a specialization in additive and subtractive manufacturing processes, this under-the-radar company holds the potential to outshine market expectations.
3DX Industries Inc. sets itself apart through its expertise in advanced manufacturing techniques. Equipped with cutting-edge 3D Metal Printing Systems, Composite Printing equipment, and a range of CNC Precision Machining Centers, the company excels in delivering exceptional results across prototyping, production, and assembly services.
To further solidify its standing, 3DX Industries Inc. recently announced substantial equipment upgrades to its 3D print lab. These upgrades include both hardware and software enhancements aimed at significantly increasing production efficiencies. The hardware upgrades incorporate new print heads, valves, and common wear parts, ensuring the highest quality and efficiency in producing parts for clients. Additionally, the software upgrades optimize the operating system, improving overall equipment performance.
Roger Janssen, President & CEO of 3DX Industries, emphasized the importance of these upgrades in staying at the cutting edge of metal printing technology and processes. By implementing the hardware and software upgrades, the company expects improved efficiencies in production time, order flow, and powder reclamation. These investments demonstrate 3DX Industries' commitment to maintaining its position as a leader in the industry.
Nicholas Coriano, VP of East Coast Operations for 3DX Industries, highlighted that these quality additions allow the company to offer clients the very best in 3D Metal Printing Services and Solutions. The upgrades not only strengthen the business but also reflect confidence in the industry's potential for growth.
3DX Industries Inc. not only excels in 3D printing but also boasts a formidable array of CNC machining centers capable of high-speed precision milling. This enables the company to cater to diverse specifications, fulfilling the demands of a wide range of clients. Furthermore, their in-house 3D Composite printer provides a cost-effective and rapid turnaround option for smaller component, prototype, and production runs.
As sectors like aerospace, automotive, and healthcare witness a growing demand for effective and affordable manufacturing solutions, 3DX Industries Inc. finds itself in an advantageous position. With its deep understanding of 3D metal printing, Binder Jetting technology, and CNC machining, the company is poised to capitalize on the ongoing growth in precision manufacturing.
With its specialization in additive and subtractive manufacturing, advanced 3D metal printing systems, and recent equipment upgrades, 3DX Industries Inc. (OTC: DDDX) presents a compelling investment opportunity within the fast growing precision manufacturing sector.
Oncotelic Therapeutics Inc. (OTC: OTLC)
OTLC is a promising player in the immune-oncology industry, poised to disrupt the landscape with its innovative RNA therapeutics and small molecule drugs. With a strong emphasis on improving outcomes for cancer patients, particularly those with rare pediatric cancers, Oncotelic presents an enticing opportunity for investors seeking potentially undervalued assets.
At the core of Oncotelic's portfolio is OT-101, a groundbreaking anti-TGF-beta RNA therapeutic that has demonstrated remarkable efficacy in clinical trials. This first-in-class treatment has shown positive single-agent activity in relapsed/refractory cancer patients and has also exhibited promising results against Covid-19. The recognition of OT-101 with rare pediatric designations from the US Food and Drug Administration further highlights its potential impact in addressing critical unmet medical needs.
Financially, Oncotelic has made significant strides. In their latest financial report, the company revealed a notable shift from a loss of approximately $10.5 million in 2021 to a net income of around $4.7 million in 2022. This positive trend is attributed to reduced research and development expenses, streamlined administrative costs, and gains from derecognition of non-financial assets. These financial advancements indicate Oncotelic's improved operational efficiency and reinforce its potential for future growth.
Adding to its innovative approach, Oncotelic recently launched a pioneering PR chatbot, demonstrating a commitment to leveraging cutting-edge AI technologies. The chatbot offers interactive responses to press releases, setting a new standard for user engagement and providing investors with seamless access to critical information.
With a robust pipeline of RNA therapeutics, significant clinical advancements, and a strong focus on rare pediatric cancers, OTLC is positioned as an intriguing investment opportunity. As the company continues to push the boundaries of immune-oncology, there is a possibility for substantial growth and increased market recognition.
OTLC represents an exciting prospect in the immune-oncology sector. Their revolutionary RNA therapeutics, remarkable clinical achievements, financial progress, and dedication to innovation contribute to the perception that they could be potentially undervalued.
Asia Broadband Inc. (OTC: AABB)
AABB emerges as a potential hidden gem on the OTC market, with its stock currently trading at $0.030 USD as of Friday, June 23, representing a 0.66% increase. As we delve into the company's recent developments, it's important to focus on its long-term potential as a hidden gem trading under 5 cents.
AABB has been making significant strides in its operations, combining its focus on producing and selling precious and base metals with its venture into the digital asset space. Notably, the company has received the initial deliveries of processing equipment for its new facility site in Etzatlan, Mexico. AABB's commitment to establishing a strong foundation for efficient operations highlights its potential for growth.
With the construction of the new processing facility in progress, AABB aims to complete it by the third quarter of 2023. This facility's expanded processing capability will be implemented once initial production levels are established, allowing for efficient revenue generation. Furthermore, the company has secured a significant stockpile of gold and silver ore in Las Jimenez, Etzatlan, Jalisco, Mexico, valued at over $800 million. This strategic acquisition aligns with AABB's expansion initiative to acquire gold production and increase its physical gold holdings.
The new processing plant, located approximately 5.8 miles from the ore stockpile, is budgeted at $3 million and initially planned to have a 200-ton-per-day processing capacity. At this level, the mill is projected to generate over $11 million in annual revenue. AABB has future plans to install a mill expansion, which will increase the processing capacity to 1,000 tons per day once the initial processing level is consistently at capacity.
As AABB progresses with its new facility and expands its presence, investors should closely monitor its growth potential in the precious metals and digital asset sectors. This emerging hidden gem on the OTC market showcases promising qualities that could capture the attention of investors seeking opportunities under 5 cents.
Unrivaled Brands Inc. (OTC: UNRV)
UNRV is a cannabis company that has been gaining attention in the market. With its current stock price of $0.021 USD and a recent 12.90% increase over the past five days, the company shows potential for growth.
In a recent press release, Unrivaled Brands announced significant developments in its financial leadership. Patty Chan, who has been serving as the company's Interim Chief Financial Officer (CFO) since September 2022, has now been appointed as the permanent CFO. Chan's expertise and strategic direction have been instrumental in the company's financial progress.
However, due to her upcoming maternity leave, Chan will temporarily step away from her role starting on June 26, 2023, and is expected to return by November 1, 2023. During her absence, Chris Rivera, a seasoned finance professional with over 20 years of experience, will serve as the Interim CFO. Rivera's extensive background includes guiding clients through complex financial transactions and working with prominent names in the industry.
Unrivaled Brands operates in the cannabis sector in California and has established itself with four dispensaries, direct-to-consumer delivery services, a cultivation facility, and a portfolio of company-owned brands. Notably, the company's brand Korova is recognized for its high-potency products across various categories.
With a dedicated financial team in place and a solid position in the cannabis market, Unrivaled Brands Inc. (OTC: UNRV) presents an intriguing opportunity for investors looking for potential hidden gems. As the company continues to expand its operations and strengthen its brand presence, monitoring its progress may be worthwhile for those interested in the cannabis industry.
Disclaimers:CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) is owned by RazorPitch Inc. and has been retained by Cambridge Consulting to assist in the production and distribution of content. 'CGR' is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport/RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR/RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.
CapitalGainsReport
Mark McKelvie
Editor
Markrmckelvie@gmail.com
585-301-7700
.
3DX INDUSTRIES, INC. 
